Business
Summit shares fall as FDA rejects closely watched PD-1/VEGF drug
BioPharma Dive · By Jonathan Gardner ·
The Brief
- The FDA rejected ivonescimab, a PD-1/VEGF drug from Summit and Akeso, for a form of lung cancer.
- The FDA refused to overlook the drug's failure to initially extend survival in that lung cancer population.
- Summit shares fell, and the decision sets back Summit's first chance to win a U.S. approval.
Why it matters
The rejection shows that the FDA will not overlook a failure to show an initial survival benefit, even for a closely watched new class of cancer drug, which matters for how science readers judge the strength of trial evidence in oncology.
Who’s affected
- investors and analysts following Summit Therapeutics
- patients and clinicians interested in EGFR-mutated lung cancer treatments
- #ivonescimab
- #pd-1/vegf
- #lung cancer
- #fda
- #drug approval
- #biotech
The FDA refused to overlook ivonescimab’s failure to initially extend survival in a form of lung cancer, setting back Summit’s first chance to win a U.S. approval.